Tiotropium + olodaterol shows clinically meaningful improvements in quality of life

Respiratory Medicine

Volumn 109, Issue 10, 2015, Pages 1312-1319

  Singh, Dave ^a   Ferguson, Gary T ^b   Bolitschek, Josef ^c   Grönke, Lars ^d   Hallmann, Christoph ^d   Bennett, Nathan ^e   Abrahams, Roger ^f   Schmidt, Olaf ^g   Bjermer, Leif ^h  

^a Medicines Evaluation Unit   (United Kingdom)

^b Pulmonary Research Institute of Southeast Michigan   (United States)

^c ELISABETHINEN HOSPITAL   (Austria)

^d BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^e BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^f Morgantown Pulmonary Clinical Research   (United States)

^g Lungen und Bronchialheilkunde   (Germany)

^h LUND UNIVERSITY   (Sweden)

Author keywords

COPD; Long acting bronchodilator; Olodaterol; Quality of life; Tiotropium

Indexed keywords

OLODATEROL PLUS TIOTROPIUM BROMIDE; PLACEBO; BENZOXAZINE DERIVATIVE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; MUSCARINIC RECEPTOR BLOCKING AGENT; OLODATEROL; TIOTROPIUM BROMIDE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG SAFETY; FORCED EXPIRATORY VOLUME; HEART DISEASE; HUMAN; LUNG FUNCTION; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SOFT MIST INHALER; ST. GEORGE RESPIRATORY QUESTIONNAIRE; TREATMENT OUTCOME; AGED; CLINICAL TRIAL; COMBINATION DRUG THERAPY; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG EFFECTS; FEMALE; INHALATIONAL DRUG ADMINISTRATION; LUNG FUNCTION TEST; MALE; MIDDLE AGED; NEBULIZER; PATHOPHYSIOLOGY; PHASE 3 CLINICAL TRIAL; PROCEDURES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

ADMINISTRATION, INHALATION; ADRENERGIC BETA-2 RECEPTOR AGONISTS; AGED; BENZOXAZINES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; MALE; MIDDLE AGED; MUSCARINIC ANTAGONISTS; NEBULIZERS AND VAPORIZERS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUALITY OF LIFE; RESPIRATORY FUNCTION TESTS; TIOTROPIUM BROMIDE;

EID: 84942987543     PISSN: 09546111     EISSN: 15323064     Source Type: Journal    
DOI: 10.1016/j.rmed.2015.08.002     Document Type: Article

References (19)

1. ® in patients with GOLD 2-4 COPD: results from two replicate 48-week studies Int. J. Chron. Obstr. Pulm. Dis. 9 2014 629 645 10.2147/COPD.S61717
2. ® in patients with GOLD 2-4 COPD: results from two 6-week crossover studies Springerplus 3 2014 419
3. P. Lange, J.-L. Aumann, A. Hamilton, K. Tetzlaff, N. Ting, and E. Derom The 24 hour lung function time profile of olodaterol once daily versus placebo and tiotropium in patients with moderate to very severe chronic obstructive pulmonary disease J. Pulm. Respir. Med. 4 2014 196 10.4172/2161-105X.1000196
4. ® versus placebo and formoterol twice daily in patients with GOLD 2-4 COPD: results from two replicate 48-week studies Int. J. Chron. Obstr. Pulm. Dis. 9 2014 697 714 10.2147/COPD.S62502
5. 2-agonist, for 4 weeks in patients with chronic obstructive pulmonary disease Respir. Med. 109 2015 596 605 10.1016/j.rmed.2015.02.012
6. Global Initiative for Chronic Obstructive Lung Disease Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease 2014 Updated 2014. Available from: http://www.goldcopd.org/uploads/users/files/GOLD-Report2014-Feb07.pdf (accessed 02.06.14)
7. R. Buhl, F. Maltais, R. Abrahams, L. Bjermer, E. Derom, G. Ferguson, and et al. Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2-4) Eur. Respir. J. 45 2015 969 979 10.1183/09031936.00136014
8. E. Derom, J. Westerman, L. Groenke, A. Hamilton, C. Li, and K.M. Beeh The 24-hour lung function profile of once-daily tiotropium and olodaterol fixed-dose combination compared with placebo and monotherapies in chronic obstructive pulmonary disease Am. J. Respir. Crit. Care Med. 189 2014 abs A6727
9. M.R. Miller, J. Hankinson, V. Brusasco, F. Burgos, R. Casaburi, A. Coates, and et al. Standardisation of spirometry Eur. Respir. J. 26 2005 319 338 10.1183/09031936.05.00034805
10. P.W. Jones Interpreting thresholds for a clinically significant change in health status in asthma and COPD Eur. Respir. J. 19 2002 398 404 10.1183/09031936.02.00063702
11. M. Decramer, A. Anzueto, E. Kerwin, T. Kaelin, N. Richard, G. Crater, and et al. Efficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trials Lancet Respir. Med. 2 2014 472 486 10.1016/S2213-2600(14)70065-7
12. M.R. Maleki-Yazdi, T. Kaelin, N. Richard, M. Zvarich, and A. Church Efficacy and safety of umeclidinium/vilanterol 62.5/25 mcg and tiotropium 18 mcg in chronic obstructive pulmonary disease: results of a 24-week, randomized, controlled trial Respir. Med. 108 2014 1752 1760 10.1016/j.rmed.2014.10.002
13. E.D. Bateman, G.T. Ferguson, N. Barnes, N. Gallagher, Y. Green, M. Henley, and et al. Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study Eur. Respir. J. 42 2013 1484 1494 10.1183/09031936.00200212
14. J.F. Donohue, M.R. Maleki-Yazdi, S. Kilbride, R. Mehta, C. Kalberg, and A. Church Efficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mcg in COPD Respir. Med. 107 2013 1538 1546 10.1016/j.rmed.2013.06.001
15. T. van der Molen, and M. Cazzola Beyond lung function in COPD management: effectiveness of LABA/LAMA combination therapy on patient-centred outcomes Prim. Care Respir. J. 21 2012 101 108
16. European Medicines Agency Anoro Summary of Product Characteristics 2014 Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002751/human-med-001754.jsp&mid=WC0b01ac058001d124 (accessed 24.03.15)
17. T.J. Witek Jr., and D.A. Mahler Minimal important difference of the transition dyspnoea index in a multinational clinical trial Eur. Respir. J. 21 2003 267 272 10.1183/09031936.03.00068503a
18. N.D. Canto, J.P. Ribeiro, J.A. Neder, and G.R. Chiappa Addition of tiotropium to formoterol improves inspiratory muscle strength after exercise in COPD Respir. Med. 106 2012 1404 1412 10.1016/j.rmed.2012.05.012
19. D.C. Berton, M. Reis, A.C. Siqueira, A.C. Barroco, L.S. Takara, D.M. Bravo, and et al. Effects of tiotropium and formoterol on dynamic hyperinflation and exercise endurance in COPD Respir. Med. 104 2010 1288 1296